Burning Rock Biotech Limited (BNR)
BNR Stock Price Chart
Explore Burning Rock Biotech Limited interactive price chart. Choose custom timeframes to analyze BNR price movements and trends.
BNR Company Profile
Discover essential business fundamentals and corporate details for Burning Rock Biotech Limited (BNR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
12 Jun 2020
Employees
674.00
Website
https://www.brbiotech.comCEO
Yusheng Han
Description
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
BNR Financial Timeline
Browse a chronological timeline of Burning Rock Biotech Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$2.31, while revenue estimate is $21.51m.
Earnings released on 9 Jun 2026
EPS came in at -$0.20 surpassing the estimated -$2.29 by +91.26%, while revenue for the quarter reached $15.68m , missing expectations by -18.34%.
Earnings released on 12 Mar 2026
EPS came in at -$0.21 surpassing the estimated -$1.40 by +84.97%, while revenue for the quarter reached $18.06m .
Earnings released on 20 Nov 2025
EPS came in at -$0.26 , while revenue for the quarter reached $18.49m .
Earnings released on 8 Sept 2025
EPS came in at -$0.15 , while revenue for the quarter reached $20.72m .
Earnings released on 6 Jun 2025
EPS came in at -$0.17 , while revenue for the quarter reached $18.28m .
Earnings released on 25 Mar 2025
EPS came in at -$1.08 surpassing the estimated -$1.40 by +22.69%, while revenue for the quarter reached $17.26m .
Earnings released on 3 Dec 2024
EPS came in at -$0.50 surpassing the estimated -$1.41 by +64.55%, while revenue for the quarter reached $18.33m .
Earnings released on 22 Aug 2024
EPS came in at -$0.14 surpassing the estimated -$1.49 by +90.58%, while revenue for the quarter reached $18.65m .
Earnings released on 29 May 2024
EPS came in at -$0.16 surpassing the estimated -$1.52 by +89.49%, while revenue for the quarter reached $17.37m .
Stock split effective on 15 May 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Mar 2024
EPS came in at -$2.20 , while revenue for the quarter reached $17.10m , beating expectations by +11.73%.
Earnings released on 30 Nov 2023
EPS came in at -$2.30 falling short of the estimated -$1.81 by -27.25%, while revenue for the quarter reached $17.46m , missing expectations by -13.26%.
Earnings released on 31 Aug 2023
EPS came in at -$1.80 surpassing the estimated -$1.89 by +4.70%, while revenue for the quarter reached $20.19m , beating expectations by +0.29%.
Earnings released on 30 May 2023
EPS came in at -$2.60 falling short of the estimated -$2.00 by -30.00%, while revenue for the quarter reached $20.73m , beating expectations by +2.96%.
Earnings released on 28 Mar 2023
EPS came in at -$3.10 falling short of the estimated -$0.38 by -715.79%, while revenue for the quarter reached $20.77m , beating expectations by +27.45%.
Earnings released on 15 Nov 2022
EPS came in at -$3.10 falling short of the estimated -$2.80 by -10.71%, while revenue for the quarter reached $21.64m , beating expectations by +0.34%.
Earnings released on 31 Aug 2022
EPS came in at -$3.70 falling short of the estimated -$3.60 by -2.78%, while revenue for the quarter reached $19.52m , missing expectations by -13.93%.
Earnings released on 31 May 2022
EPS came in at -$3.90 falling short of the estimated -$2.30 by -69.57%, while revenue for the quarter reached $21.33m , missing expectations by -2.24%.
Earnings released on 21 Mar 2022
EPS came in at -$3.80 falling short of the estimated -$0.24 by -1.51k%, while revenue for the quarter reached $23.14m , beating expectations by +7.70%.
Earnings released on 15 Nov 2021
EPS came in at -$2.50 falling short of the estimated -$1.90 by -31.58%, while revenue for the quarter reached $19.62m , missing expectations by -6.00%.
Earnings released on 31 Aug 2021
EPS came in at -$3.00 falling short of the estimated -$1.50 by -100.00%, while revenue for the quarter reached $19.68m .
BNR Stock Performance
Access detailed BNR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
